<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023829</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-P-0011</org_study_id>
    <secondary_id>CDR0000068868</secondary_id>
    <secondary_id>CAN-NCIC-PR9</secondary_id>
    <nct_id>NCT00023829</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer</brief_title>
  <official_title>Phase III Randomized Study of Adjuvant Therapy for High Risk pT3N0 Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can&#xD;
      stimulate the growth of prostate cancer cells. Drugs such as, flutamide or bicalutamide may&#xD;
      stop the adrenal glands from producing androgens. Giving radiation therapy with hormone&#xD;
      therapy after surgery to remove the tumor may kill any tumor cells remaining after surgery&#xD;
      and be an effective treatment for stage II or stage III prostate cancer. It is not yet known&#xD;
      if radiation therapy combined with hormone therapy is more effective than either radiation&#xD;
      therapy alone or hormone therapy alone in treating stage II or stage III prostate cancer.&#xD;
      (Hormone therapy alone group closed as of 12/9/2002.)&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of adjuvant radiation&#xD;
      therapy plus hormone therapy to that of radiation therapy alone or hormone therapy alone in&#xD;
      treating patients who have stage II or stage III prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall survival, disease-free survival, freedom from distant metastases,&#xD;
           and freedom from PSA failure in patients with high-risk stage II or III prostate cancer&#xD;
           treated in the adjuvant setting with radiotherapy and hormonal therapy vs radiotherapy&#xD;
           alone.&#xD;
&#xD;
        -  Compare the qualitative and quantitative toxic effects of these regimens in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      seminal vesicle invasion (yes vs no), preoperative PSA (10 ng/mL or less vs greater than 10&#xD;
      ng/mL), Gleason score (2-6 vs 7 vs 8-10), positive surgical margins (yes vs no), and&#xD;
      neoadjuvant hormonal therapy (yes vs no). Patients are randomized to 1 of 3 treatment arms.&#xD;
      (Arm III closed to accrual as of 12/9/2002.)&#xD;
&#xD;
        -  Arm I: Patients undergo radiotherapy once daily 5 days a week for 7 weeks. Beginning the&#xD;
           first day of radiotherapy, patients also receive hormonal therapy comprising a&#xD;
           luteinizing-hormone-releasing hormone agonist once every 1-4 months for 2 years AND oral&#xD;
           flutamide 3 times daily OR oral bicalutamide once daily for 1 month.&#xD;
&#xD;
        -  Arm II: Patients undergo radiotherapy as in arm I.&#xD;
&#xD;
        -  Arm III (Closed to accrual as of 12/9/2002):Patients receive hormonal therapy as in arm&#xD;
           I.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,398 patients (699 per treatment arm) will be accrued for this&#xD;
      study within 5 years. (Arm III closed to accrual as of 12/9/2002.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of randomization to the date of death due to any cause</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>From the date of randomization to the date of first documented local progression or distant failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Failure</measure>
    <time_frame>From the date of randomization to the date of frist documented metastatic disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Failure (detectable PSA)</measure>
    <time_frame>From the date of randomization to the date of developing a PSA of 0.5 ng/ml or greater over the entry PSA</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>LH-RH agonist plus radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation therapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy alone to 63.0 - 66.6 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LH-RH agonist alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <arm_group_label>LH-RH agonist alone</arm_group_label>
    <arm_group_label>LH-RH agonist plus radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
    <arm_group_label>LH-RH agonist alone</arm_group_label>
    <arm_group_label>LH-RH agonist plus radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>releasing hormone agonist therapy</intervention_name>
    <arm_group_label>LH-RH agonist alone</arm_group_label>
    <arm_group_label>LH-RH agonist plus radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>LH-RH agonist alone</arm_group_label>
    <arm_group_label>LH-RH agonist plus radiation therapy</arm_group_label>
    <arm_group_label>Radiation therapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>LH-RH agonist plus radiation therapy</arm_group_label>
    <arm_group_label>Radiation therapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
               -  T2-3, N0, M0&#xD;
&#xD;
               -  No metastatic disease&#xD;
&#xD;
          -  High-risk for PSA relapse as defined by Gleason score 7 or higher and ≥ 1 of the&#xD;
             following OR Gleason score &lt; 7 and ≥ 2 of the following:&#xD;
&#xD;
               -  Preoperative PSA &gt; 10 ng/mL&#xD;
&#xD;
               -  Positive surgical margins&#xD;
&#xD;
               -  Seminal vesicle invasion&#xD;
&#xD;
          -  Preoperative PSA ≤ 40.0 ng/mL&#xD;
&#xD;
          -  Postoperative PSA ≤ 0.2 ng/mL&#xD;
&#xD;
          -  Negative lymph node status by lymph node sampling or dissection&#xD;
&#xD;
               -  If lymph node status is unknown, must have &lt; 5% risk of involvement by Roach&#xD;
                  formula&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 130,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 11.4 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  ALT ≤ 3 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent invasive malignancy within the past 5 years except&#xD;
             superficial nonmelanoma skin cancer&#xD;
&#xD;
          -  No other major medical or psychiatric illness that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 5 years since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 60 days since prior finasteride&#xD;
&#xD;
          -  At least 90 days since prior testosterone&#xD;
&#xD;
          -  Prior pharmacologic androgen ablation for prostate cancer allowed if initiated within&#xD;
             the past 10 months (must switch to study ablation therapy OR discontinue therapy if&#xD;
             randomized to receive radiotherapy only)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis&#xD;
&#xD;
          -  No concurrent intensity-modulated radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior orchiectomy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K. Valicenti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Choo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

